APOA1 and early-onset autosomal dominant Alzheimer disease: These investigators further argue that manipulation of HDL transcytosis across the BBB to increase delivery of plasma apoA-I may, in turn, facilitate increasing the transport of “HDL-like synthetic particles” containing therapeutic drugs across the BBB to treat neurodegenerative disorders such as Alzheimer’s disease [32] (cf. [28,33,34,35,36,37,38,39,40,41,42]).